Xiaoxiao Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaoxiao Zhou has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Anatoli Yashin
Social Science Research Institute Duke University Durham North Carolina USA
1 shared publication- Andrew Sims
University of Mississippi Medical Center
1 shared publication - D. Leann Long
Department of Biostatistics and Data Science, Wake Forest University School of Medicine , Winston-Salem, NC
1 shared publication Haotian Zou
Department of Biostatistics & Bioinformatics Duke University Durham North Carolina USA
1 shared publicationIgor Akushevich
Social Science Research Institute Duke University Durham North Carolina USA
1 shared publication- Jinhong Cui
University of Alabama at Birmingham
1 shared publication
Latest Publications
- 15 July 2026
- Published by SAGE Publications in Statistical Methods in Medical Research
- Vol. 35 (9) , 1882-1896
Bayesian mediation analysis for zero-inflated mediator
Mediation analysis is a powerful tool for exploring the causal relationships between exposures and outcomes that are mediated by intermediate variables. In this paper, we propose a flexible Bayesian mediation analysis framework to accommodate zero-inflated mediators, compatible with a wide range of outcome distributions. This novel technique employs Bayesian models for both the mediator and the outcome, utilizing Markov Chain Monte Carlo algorithms for parameter estimation. While addressing the challenges posed by an excess of zeros, we further decompose the mediation effects into components influenced by either the probability of zero or the mean of the non-zero distribution in the mediator. An associated R package mediationBayes ( https://github.com/jhcuibst/mediationBayes.git ) has been developed to facilitate the application of this framework. Through comprehensive simulation studies, we demonstrate that our method outperforms alternatives in terms of the accuracy of point estimates, coverage probabilities, and the precision of the mediation effects decomposition. We further illustrate the practical applicability of our method by conducting an analysis on the REasons for Geographic And Racial Differences in Stroke Study to investigate the mediating influence of smoking pack-years on the association between educational levels and incident hypertension, where mediation effects are quantified on a risk ratio scale for binary outcomes.
- 15 July 2026
- Published by SAGE Publications in Statistical Methods in Medical Research
- Vol. 35 (9) , 1882-1896
Bayesian mediation analysis for zero-inflated mediator
Mediation analysis is a powerful tool for exploring the causal relationships between exposures and outcomes that are mediated by intermediate variables. In this paper, we propose a flexible Bayesian mediation analysis framework to accommodate zero-inflated mediators, compatible with a wide range of outcome distributions. This novel technique employs Bayesian models for both the mediator and the outcome, utilizing Markov Chain Monte Carlo algorithms for parameter estimation. While addressing the challenges posed by an excess of zeros, we further decompose the mediation effects into components influenced by either the probability of zero or the mean of the non-zero distribution in the mediator. An associated R package mediationBayes ( https://github.com/jhcuibst/mediationBayes.git ) has been developed to facilitate the application of this framework. Through comprehensive simulation studies, we demonstrate that our method outperforms alternatives in terms of the accuracy of point estimates, coverage probabilities, and the precision of the mediation effects decomposition. We further illustrate the practical applicability of our method by conducting an analysis on the REasons for Geographic And Racial Differences in Stroke Study to investigate the mediating influence of smoking pack-years on the association between educational levels and incident hypertension, where mediation effects are quantified on a risk ratio scale for binary outcomes.
- Open Access
- 1 April 2024
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 10 (2) , e12471
Assessing tilavonemab efficacy in early Alzheimer's disease via longitudinal item response theory modeling
INTRODUCTION: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by declines in cognitive and functional severities. This research utilized the Clinical Dementia Rating (CDR) to assess the influence of tilavonemab on these deteriorations. METHODS: Longitudinal Item Response Theory (IRT) models were employed to analyze CDR domains in early‐stage AD patients. Both unidimensional and multidimensional models were contrasted to elucidate the trajectories of cognitive and functional severities. RESULTS: We observed significant temporal increases in both cognitive and functional severities, with the cognitive severity deteriorating at a quicker rate. Tilavonemab did not demonstrate a statistically significant effect on the progression in either severity. Furthermore, a significant positive association was identified between the baselines and progression rates of both severities. DISCUSSION: While tilavonemab failed to mitigate impairment progression, our multidimensional IRT analysis illuminated the interconnected progression of cognitive and functional declines in AD, suggesting a comprehensive perspective on disease trajectories. Highlights: Utilized longitudinal Item Response Theory (IRT) models to analyze the Clinical Dementia Rating (CDR) domains in early‐stage Alzheimer's disease (AD) patients, comparing unidimensional and multidimensional models. Observed significant temporal increases in both cognitive and functional severities, with cognitive severity deteriorating at a faster rate, while tilavonemab showed no statistically significant effect on either domain's progression. Found a significant positive association between the baseline severities and their progression rates, indicating interconnected progression patterns of cognitive and functional declines in AD. Introduced the application of multidimensional longitudinal IRT models to provide a comprehensive perspective on the trajectories of cognitive and functional severities in early AD, suggesting new avenues for future research including the inclusion of time‐dependent random effects and data‐driven IRT models.
- 1 April 2024
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 10 (2) , e12471
Open AccessAssessing tilavonemab efficacy in early Alzheimer's disease via longitudinal item response theory modeling
INTRODUCTION: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by declines in cognitive and functional severities. This research utilized the Clinical Dementia Rating (CDR) to assess the influence of tilavonemab on these deteriorations. METHODS: Longitudinal Item Response Theory (IRT) models were employed to analyze CDR domains in early‐stage AD patients. Both unidimensional and multidimensional models were contrasted to elucidate the trajectories of cognitive and functional severities. RESULTS: We observed significant temporal increases in both cognitive and functional severities, with the cognitive severity deteriorating at a quicker rate. Tilavonemab did not demonstrate a statistically significant effect on the progression in either severity. Furthermore, a significant positive association was identified between the baselines and progression rates of both severities. DISCUSSION: While tilavonemab failed to mitigate impairment progression, our multidimensional IRT analysis illuminated the interconnected progression of cognitive and functional declines in AD, suggesting a comprehensive perspective on disease trajectories. Highlights: Utilized longitudinal Item Response Theory (IRT) models to analyze the Clinical Dementia Rating (CDR) domains in early‐stage Alzheimer's disease (AD) patients, comparing unidimensional and multidimensional models. Observed significant temporal increases in both cognitive and functional severities, with cognitive severity deteriorating at a faster rate, while tilavonemab showed no statistically significant effect on either domain's progression. Found a significant positive association between the baseline severities and their progression rates, indicating interconnected progression patterns of cognitive and functional declines in AD. Introduced the application of multidimensional longitudinal IRT models to provide a comprehensive perspective on the trajectories of cognitive and functional severities in early AD, suggesting new avenues for future research including the inclusion of time‐dependent random effects and data‐driven IRT models.